By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology have been presented. According to news reporting from Milan, Italy, by NewsRx journalists, research stated, "Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2) positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination."
The news correspondents obtained a quote from the research from the Department of Oncology, "Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients. Eighty-six patients underwent F-18-FDG PET/CT at baseline and weeks 2 and 6 of anti-HER2 treatment. An imaging core laboratory provided central validation, and 2 independent reviewers, masked to assigned treatment arm and clinical outcomes, performed consensus F-18-FDG PET/CT readings. Maximum standardized uptake value (SUVmax) reductions from baseline were used to measure metabolic response. Seventy-seven of the 86 enrolled patients presented an evaluable baseline F-18-FDG PET/CT scan; of these, 68 and 66 were evaluable at weeks 2 and 6, respectively. Metabolic responses in the primary tumors were evident after 2 wk of targeted therapy and correlated highly with metabolic responses at week 6 (R-2 = 0.81). pCRs were associated with greater SUVmax reductions at both time points. Mean SUVmax reductions for pCR and non-pCR, respectively, were 54.3% versus 32.8% at week 2 (P = 0.02) and 61.5% versus 34.1% at week 6 (P = 0.02). F-18-FDG PET/CT metabolic response rates at weeks 2 and 6 were 71.6% and 60%, respectively using European Organization for Research and Treatment of Cancer criteria; pCR rates were twice as high for F-18-FDG PET/CT responders than nonresponders (week 2: 42% vs. 21%, P = 0.12; week 6: 44% vs. 19%, P = 0.05)."
According to the news reporters, the research concluded: "Early metabolic assessment using F-18-FDG PET/CT can identify patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy."
For more information on this research see: F-18-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. Journal of Nuclear Medicine, 2013;54(11):1862-1868. Journal of Nuclear Medicine can be contacted at: Soc Nuclear Medicine Inc, 1850 Samuel Morse Dr, Reston, VA 20190-5316, USA (see also Oncology).
Our news journalists report that additional information may be obtained by contacting G. Gebhart, Ist Nazl Tumori, Dept. of Oncol, I-20133 Milan, Italy. Additional authors for this research include C. Gamez, E. Holmes, J. Robles, C. Garcia, M. Cortes, E. de Azambuja, K. Fauria, V. Van Dooren, G. Aktan, M.A. Coccia-Portugal, S.B. Kim, P. Vuylsteke, H. Cure, H. Eidtmann, J. Baselga, M. Piccart, P. Flamen and S. Di Cosimo.
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Biotechnology, Milan, Italy, Drugs, Europe, Oncology, Lapatinib, Treatment, Trastuzumab, Chemotherapy, Breast Cancer, Women's Health, EGFR Inhibitors, HER2 Inhibitors, Medical Devices, Tyrosine Kinase Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC